The purpose of the study is to understand how the body handles etavopivat and to check for any unwanted effects during a 24-week treatment period. During the study, doctors will measure how much medicine is in the blood after a single dose and during regular treatment. They will also monitor for any side effects and record how often treatment needs to be stopped or changed. The study will look at whether the medicine helps increase the level of a substance in the blood called hemoglobin, which carries oxygen throughout the body. Doctors will also track painful episodes called vaso-occlusive crises, which are common in sickle cell disease when blood flow becomes blocked.

Participants will be divided into different groups based on their age, starting with older children and then including younger ones. Some children in the study may already be taking other treatments for sickle cell disease, such as hydroxyurea, crizanlizumab, or L-glutamine, and can continue these medicines if their dose has been stable. The study will also measure changes in tiredness levels and check blood flow in the brain using a test called transcranial Doppler ultrasonography in children over 2 years old. After the first 24 weeks, there will be an extension period where the medicine can continue to be given while doctors keep checking for safety.

During the study, the treatment will be administered over a period of up to five days. The researchers will observe the impact of the medication on the amount of opioid, a type of strong pain medicine, required by patients during their time in the hospital. The total hospital stay for these episodes may last up to 21 days.

The purpose of the study is to find out if adding lidocaine hydrochloride to morphine hydrochloride can reduce the total amount of morphine needed to control pain during a vaso-occlusive crisis. The study is designed so that neither the patients nor the doctors will know which treatment each patient is receiving during the trial, which helps ensure fair results. Patients will be randomly assigned to receive either the combination treatment or morphine alone.

During the study, researchers will measure how much morphine each patient uses, track changes in pain levels using a pain rating scale, monitor certain substances in the blood that may indicate how the body is responding to treatment, and watch for any unwanted effects that morphine might cause. The study will help doctors understand whether combining these two medications provides better pain relief with less morphine compared to using morphine by itself.

The research evaluates how well the kidneys filter blood (called glomerular filtration) and how this affects morphine processing in the body. By measuring kidney function using iohexol clearance (a reference method) and comparing it to a kidney function estimation tool (CKD-Epi score), researchers hope to determine when standard morphine doses might not provide adequate pain relief for certain patients.

Understanding the relationship between kidney function and morphine effectiveness could help doctors identify which patients need higher initial doses of pain medication. This would allow for more personalized pain management strategies for people with sickle cell disease during painful crises, potentially improving treatment outcomes and patient comfort.

The purpose of the study is to understand how Mitapivat affects brain oxygen use and blood flow in people with Sickle Cell Disease. Participants in the study will take Mitapivat and undergo several tests, including MRI scans, over a period of 12 months. These tests will help researchers see how the medication impacts brain function and blood circulation.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable information on whether Mitapivat can be an effective treatment for improving brain oxygen use in individuals with Sickle Cell Disease.

Participants in the study will receive a single dose of CTX001 through an infusion, which is a way of delivering the treatment directly into the bloodstream. The study will monitor the participants over time to see if the treatment helps reduce the number of painful episodes and hospital visits related to sickle cell disease. The study will also look at the safety of the treatment by checking for any side effects or changes in health markers like blood counts and vital signs.

The trial aims to find out if CTX001 can help children with severe sickle cell disease by reducing the frequency of painful crises and improving their overall health. The study will track the participants’ progress for several months to gather information on how well the treatment works and how safe it is. This research could lead to new ways to manage and treat sickle cell disease in the future.

Participants in the study will take Voxelotor orally over a period of up to 52 weeks. Throughout the study, various health assessments will be conducted to monitor the effects of the medication. These assessments will include measuring the levels of hemoglobin in the blood, which is a protein in red blood cells that carries oxygen. The study will also look at other health indicators such as blood flow to the brain, kidney function, and overall physical performance.

The study aims to see if Voxelotor can improve the health of people with sickle cell disease by reducing the damage to their red blood cells and improving blood flow and organ function. Participants will be closely monitored for any changes in their condition and any side effects from the medication. The results of this study could provide valuable information about the potential benefits of Voxelotor for individuals living with sickle cell disease.

Before receiving the modified cells, patients will be given medications including plerixafor to help collect their blood stem cells, and busulfan to prepare their body for the treatment. The modified stem cells are then given back to the patient through an intravenous infusion. This is a type of cell therapy where the patient’s own cells are changed in a laboratory to help them produce a special form of hemoglobin that can prevent the sickling of red blood cells.

After receiving the treatment, patients will be monitored to see how well the modified cells work in their body and if they experience fewer painful crisis events related to their disease. The study will track various aspects of the patient’s health, including how well the new cells grow in their body and whether the treatment reduces hospital stays and complications from sickle cell disease.

The purpose of the study is to evaluate how effective and safe crizanlizumab is in reducing the number of painful episodes, known as vaso-occlusive crises, that lead to healthcare visits in people with sickle cell disease. Participants in the study will receive either crizanlizumab or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will last for about a year, during which time participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will collect information on how often participants experience vaso-occlusive crises, how long these episodes last, and any other health changes that occur. This information will help determine if crizanlizumab is a beneficial treatment option for managing sickle cell disease. The study aims to provide valuable insights into improving care for individuals living with this condition.

The purpose of this research is to continue providing crizanlizumab treatment to patients with Sickle Cell Disease who have previously participated in other studies of this medication. The treatment will be administered through an intravenous line every few weeks, with each dose calculated based on the patient’s weight. The maximum dose will be 7.5 milligrams per kilogram of body weight.

During the study, which may last up to 120 months, patients will receive regular infusions of crizanlizumab. The medical team will monitor the patients’ health and track any side effects that may occur during the treatment. This monitoring will help ensure patient safety throughout the study period.

The purpose of this study is to evaluate the long-term safety of CTX001 in patients who have already received this treatment for either Sickle Cell Disease or Transfusion-dependent Thalassemia. Participants in the study will be monitored over an extended period to observe any new health issues, such as new cancers or blood disorders, and to track their overall health and well-being. The study will also look at changes in hemoglobin levels and the presence of the intended genetic changes in the blood and bone marrow over time.

Throughout the study, participants will undergo regular check-ups to ensure their safety and to gather information on how the treatment affects their health. This includes monitoring for any serious side effects and assessing the overall impact on their quality of life. The study is designed to provide valuable insights into the long-term effects of CTX001 and its potential benefits for individuals with these challenging blood disorders.

The purpose of the study is to evaluate the effectiveness and safety of a single dose of CTX001 in patients with these conditions. Participants will receive the treatment and be monitored over time to see how their levels of fetal hemoglobin change. The study will also look at the safety of the treatment by checking for any side effects and monitoring the health of the participants. Other medications used in the study include Filgrastim, Busulfan, and Plerixafor, which are used to prepare the body for the main treatment.

During the study, participants will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. They will be closely monitored by healthcare professionals to ensure their safety and to track the effectiveness of the treatment. The study aims to provide valuable information on whether this new approach can help reduce the need for blood transfusions and improve the quality of life for people with these challenging conditions.

The purpose of the study is to evaluate the effectiveness and safety of a single dose of Exa-cel in adolescents and adults with severe Sickle Cell Disease. Participants will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. Before receiving Exa-cel, participants will undergo a conditioning process with a medication called Busulfan, which helps prepare the body for the new treatment. The study will monitor participants over time to see if the treatment helps reduce the number of severe pain episodes and other complications associated with the disease.

Throughout the study, researchers will keep track of various health indicators to ensure the treatment is safe and effective. This includes monitoring for any side effects, changes in blood cell levels, and overall health improvements. The study aims to provide valuable information on whether Exa-cel can be a beneficial treatment option for those living with severe Sickle Cell Disease.